Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics, Inc. Announces Enrollment of First Patient in Phase II Cervical Cancer Trial for Triapine®

BusinessWire.com - November 2013

Nanotherapeutics, Inc. announced today enrollment of the first patient into a Phase II cervical cancer trial for Triapine®, sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI).

Full Article

Copyright 2016 NANOTHERAPEUTICS, INC.  All rights reserved.